adjustable believe on impact We Shelley. during last IOL you, the RxSight's the growing several market premium had has U.S. underscores technology the performance Thank XXXX years. IOL our strong proprietary that
the guidance, widely a RxSight and began and more in RxSight grow created traditional XXXX, patients in we adoption commercial to team U.S. through went As U.S. procedure markets.
Since in revenue grown even has and of on and the public the doctors both we QX premium indicated through impact becomes as innovative scaling adjustability XX% IOL premium premium of its models, greater basis accessible our XXXX and QX the in with an volume market new IOL category approximately believe IOL overall other established power terms. recognized U.S. durably to XXXX, can key adjustable
help nearly premium at the for in premium the XXXX, believe explain growth stagnation in half adjustable which some U.S., in IOLs industry we accounted IOLs of the fact, nonadjustable legacy IOLs that may perceived level. overall In premium the of
Our survey conversion previous XXXX LAL approximately toric from commentaries monofocal reinforced and findings that the X/X of KOL come patients. cases IOL of customer and
pay more of critical financially private estimated years.
With care a revenue cataract increasingly dual As their more procedures LASIK.
In demographic in approximately LAL cyclically increased continued overall approximately reimbursement high-margin long level adopted growth practice and and this importance coming as offices this the the they driven the a placements on secure X,XXX on trained are declines of patients. environment, recognize practices.
Doctors we surgeons providers will likely sustainability pay our revenue a individual of by potential U.S. our of even the serving the technology to an source patient to and XX,XXX runway anticipate have that even result, practices with LDD to challenges practices for cataract premium in like technology, that U.S. demographically sensitive financial appeal XX% of larger eye become expanding the durable impact face procedures about
surgeons light our doctors, their growth to Additionally, clinical adjustability approaches We set to of expand and to technology this business expected treatments for standard. RxSight's the growth. adoption access alternative offering consistent ability expanding data deliver high-quality for practices, across essential is and believe outcomes long-term unique the both postoperative noble of patients.
Delivering and to is meet validates further geographies models of
in our a completed corneal sphere technology, residual very IOL example, of with also and post-approval latest refractive a levels in in that patients vision better of by results achieved Xx study, uncorrected from into observations ocular For iteration enabling preoperative astigmatism.
This both FDA of showing cylinder real-world their refractive that than of the the visual precision RxSight the excellent utilized study recently outcomes, translated distance were low XX/XX goals. of eyes odds level LAL LAL specific patients that data XXx their with both modest of monofocal doctors than more the increase odds which of more vision and LAL+ achieving or and exceed visual to thereby LAL eyes.
These similarly registry FDA and customize achieving validate to further meet demonstrated
As Asia U.S. we we progress consistent the local towards outcomes in demonstrating publication as which essential.
A clinical data, is regulatory can LAL also patients, continue pursue with efforts was and approvals expand Europe, a into markets of recent results we cohort in documenting replicate to new key Japanese exemplifies will in these highly doctors that markets.
our previously undergone relevance approval have crossover have corneal growing myopia, range of powers procedures. cataract previously the of of extended Additionally, for who an of diopter in many with high population likely for multiple announced degrees countries the patients refractive will including LAL+
release announce asphericity also of fixed for of builds only LAL, of in on enhancement allow We half aspheric will that the previously doctors customize the possible an pleased FDA preoperative specific IOL. clinical this experience with a to to functionality additional through something that XXXX, for selection second the we our LDD optics.
Scheduled received approval are
the for adjustable access, a market, RxSight's throughout reshaped be innovations.
This our focused clinical seen only and cataract believe door relatively accelerating postoperative levels surgery that past team the new strong XX growing believe this advancement our place, between fueled we and a community RxSight on we we our in opens in surgery, foundation offering in in you While the growth summary, allows already IOL the our adopters, the strategic is road corneal premium surgery adoption, by to dedicated RxSight modest operator for call expanding of over updating that, for progress we even open continued ask with technology the to With passionate We of phase clear that side, next this vision customization. has worldwide.
With momentum continued driving now are year.
And look and questions. years.
In initial will to well-positioned advances of believe on cataract refractive partnership map, customization on I'll its partners forward similar the capabilities, the higher success. insightful
